Edwards Lifesciences price target raised by $2 at Truist, here’s why

Truist raised the firm’s price target on Edwards Lifesciences to $78 from $76 and keeps a Buy rating on the shares. The company’s Investor Day highlighted drivers to support 10% or more in revenue and earnings growth in FY25 and beyond through a combo of indication expansion and prod innovation across the company’s TAVR and TMTT franchises, the analyst tells investors in a research note. The 8%-10% FY24 constant currency revenue guide matched expectations, while a commitment to 10% in FY25 raised some eyebrows as a “high bar”, the firm added.